Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

17.00
-0.5400-3.08%
Pre-market: 17.190.1900+1.12%09:10 EDT
Volume:4.22M
Turnover:72.00M
Market Cap:13.56B
PE:-15.21
High:17.62
Open:17.30
Low:16.80
Close:17.54
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.56
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.53
PE(LYR):-11.77

Loading ...

Stock Track | Summit Therapeutics Soars 5.03% in After-Hours on Positive Lung Cancer Drug Trial Results

Stock Track
·
Jun 02

Assessing Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III And Phase II Trial Results

Simply Wall St.
·
Jun 02

Summit Therapeutics Shares Fall 10%, Reversing Premarket Gains

THOMSON REUTERS
·
Jun 01

Stock Track | Summit Therapeutics Plummets 7.41% Intraday Amid Investor Skepticism Over Lung Cancer Drug Data

Stock Track
·
Jun 01

Stock Track | Summit Therapeutics Plunges 5.25% in Pre-Market Amid Investor Skepticism Over Lung Cancer Drug Data

Stock Track
·
Jun 01

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Dow Jones
·
Jun 01

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)

TIPRANKS
·
Jun 01

Summit Therapeutics Shares Rise 4.1% Premarket After Co's Lung Cancer Drug With China-Based Partner Shows 15% Higher Survival Rate Than Rival's

THOMSON REUTERS
·
Jun 01

Summit Therapeutics Says Ivonescimab Improves Survival Over Tislelizumab in Phase III Lung Cancer Trial

MT Newswires Live
·
Jun 01

Stock Track | Summit Therapeutics Soars 9.06% in Pre-market on Positive Lung Cancer Drug Trial Results

Stock Track
·
Jun 01

Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results

Stock Track
·
Jun 01

Summit Therapeutics posts HARMONi-6 ASCO 2026 plenary slides on ivonescimab in squamous NSCLC

Reuters
·
Jun 01

Summit Therapeutics announces OS results from Phase 3 HARMONi-6 trial

TIPRANKS
·
May 31

Summit Therapeutics presents new results from AK112-206 trial

TIPRANKS
·
May 31

CORRECTED-Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)

Reuters
·
May 31

BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says

MT Newswires Live
·
May 28

Assessing Summit Therapeutics (SMMT) Valuation As Ivonescimab Development Draws Fresh Investor Attention

Simply Wall St.
·
May 24

Summit Therapeutics Downgraded by H.C. Wainwright Amid Merck ADC Data Concerns

Deep News
·
May 23

This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday

Benzinga
·
May 23